2025 World Conference on Lung Cancer (WCLC)

Attendee Access: This product is for live/hybrid conference attendees.
Extended Conference Access: Click here to purchase.
Questions? Contact education@iaslc.org.

The IASLC World Conference on Lung Cancer is the largest international gathering in the field of lung cancer and thoracic oncology. The conference offers ground-breaking education in its wide-ranging and multidisciplinary content. In addition to traditional abstract presentations and lectures by world renowned speakers, the conference provided hands-on workshops, interactive sessions, as well as several sessions dedicated to subspecialties like nurses, patients, and advocates.

Live Activity Dates: September 6 - 9, 2025
Enduring Activity Launch Date: September 9, 2025
Enduring Activity Expiration Date: September 8, 2026

The IASLC World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to:

Advance Multidisciplinary Care in Lung Cancer: Make use of evidence-based strategies across surgery, radiation, medical oncology, pathology, radiology, nursing, and supportive care to optimize outcomes for patients with lung cancer.
Evaluate Innovations in Screening, Early Detection, and Risk Reduction: Assess advances in lung cancer screening programs, novel imaging, and the role of prevention strategies—including tobacco control and occupational risk mitigation—to reduce disease burden.
Implement Personalized Treatment Approaches: Apply current evidence on molecular testing, biomarker-driven therapies, and targeted treatments—including ADCs, TKIs, and immunotherapies—to tailor interventions for diverse patient populations.
Explore the Evolving Landscape of Immunotherapy: Critically evaluate emerging data on immune checkpoint inhibitors, combination strategies, bispecifics, and their management in special populations such as patients with autoimmune diseases, transplants, or brain metastases.
Enhance Management of Early and Locally Advanced Disease: Discuss best practices and evolving approaches for resectable and unresectable NSCLC, including neoadjuvant, adjuvant, and perioperative strategies, as well as advanced radiotherapy and ablative techniques.
Address Challenges in SCLC, NENs, and Rare Thoracic Tumors: Examine new diagnostic, molecular, and therapeutic developments in small cell lung cancer, neuroendocrine tumors, mesothelioma, and thymic malignancies to improve patient care.
Integrate Novel Diagnostic and Monitoring Tools: Evaluate the utility of advanced imaging, multiomic analyses, liquid biopsies (including ctDNA and methylation), and digital pathology in staging, treatment response, and surveillance.
Improve Care Delivery in Resource-Limited and Diverse Settings: Identify barriers and implement solutions for equitable access to molecular testing, precision oncology, and advanced therapies in low- and middle-income countries and underserved populations.
Promote Shared Decision-Making and Patient-Centered Care: Model approaches to communication, survivorship planning, and addressing quality of life, emphasizing patient preferences, advocacy, and integrative care.
Foster Interactive Learning and Collaborative Problem-Solving: Apply new knowledge to complex clinical scenarios and enhance decision-making in lung cancer care by engaging in case-based discussions, polling, and multidisciplinary debates.

Umberto Malapelle, PhD
Jarushka Naidoo, MD
Isabelle Opitz, MD
Noemi Reguart, MD, PhD

Click here to view the full list of 2025 WCLC Faculty and their Disclosures.

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 55.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Countries that accept ACCME-accredited continuing medical education (CME):
The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians.

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There is a fee for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out, if applicable.
Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.